Cereno Scientific

Cereno Scientific is a clinical-stage biotechnology company focused on developing innovative treatments for rare and common cardiovascular diseases. The company has a diversified portfolio of three drug candidates: CS1 in Phase II, CS014 in Phase I, and CS585 in preclinical development. Cereno's lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. CS1 is currently being evaluated in a Phase II clinical trial for the treatment of the rare disease Pulmonary Arterial Hypertension (PAH).

Cereno Scientific is headquartered in GoCo Health Innovation City, Gothenburg, Sweden, and has a US subsidiary: Cereno Scientific Inc., based in Kendall Square, Boston, Massachusetts. Cereno Scientific is listed on Nasdaq First North (CRNO B). The company's mission is to improve the quality of life and prolong the lives of people with cardiovascular diseases by developing safe and effective treatments.

Cereno Scientific is a clinical-stage biotech company dedicated to developing innovative treatments for rare and common cardiovascular diseases. Their primary focus is on creating safe and effective treatments that improve quality of life and extend life expectancy for patients suffering from conditions with significant unmet medical needs, such as thrombosis, fibrosis, high blood pressure, and inflammation. They achieve this through a diversified portfolio of clinical and preclinical drug candidates, including CS1 in Phase II, CS014 in Phase I, and CS585 in preclinical development.

Cereno Scientific promotes a culture of innovation and collaboration focused on developing effective and safe treatments for patients with rare and common cardiovascular diseases. The company values teamwork, scientific rigor, and a dedication to improving the quality of life for those affected by these conditions. Their commitment to patient-centric research is evident in their Phase II trial with CS1, where they utilize Abbott's CardioMEMS HF System to monitor lung pressure and other heart-lung functions in patients. This dedication to advancing scientific knowledge and providing better treatments for patients underscores Cereno Scientific's commitment to their mission.